IRUBIS GmbH is a company focused on advancing bioprocess monitoring through innovative mid-infrared (MIR) spectroscopy technology. The company develops Monipa, a Process Analytical Technology (PAT) solution that enables robust, real-time, inline measurement of proteins, excipients, mRNA, and pDNA during bioprocessing.
Founded in 2017 and based in Munich, Germany, IRUBIS aims to accelerate the development of life-saving medications by simplifying and improving bioprocess efficiency. Monipa eliminates the need for complex calibration and provides reliable data within minutes, supporting faster decision-making and reduced batch loss in downstream processing.
The company has received multiple grants and awards, including funding from the European Innovation Council (EIC) Accelerator and support from investors such as High-Tech Gründerfonds and Verve Ventures. With a growing team of international experts, IRUBIS continues to expand its technological edge and global commercial presence.